Other languages Almirall, S.A.

Equities

ALM

ES0157097017

Market Closed - BME Other stock markets 11:35:26 2024-04-26 EDT			5-day change	1st Jan Change
8.57 ^EUR	+1.24%		+4.00%	+1.72%

03-13	Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	MT
02-19	Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LE OPINIONI DEGLI ANALISTI DEL GIORNO : Moncler, Boreo, Fugro, STMicroelectronics, Alfen, Iberdrola, Roche, Temenos, Akzo Nobel...	04-25
IN DIRETTA DAI MERCATI: Moncler, ENI, Webuild, Iberdrola, Adyen, SAES Getters, Xiaomi, Iberdrola, STMicro, Meta...	04-25
EN DIRECTO DESDE LOS MERCADOS: Repsol, Almirall, Enagás, Iberdrola, Técnicas Reunidas, Aedas, Iberdrola, STMicro, Meta...	04-25
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	03-13
EN DIRECTO DESDE LOS MERCADOS: Grifols, Almirall, Santander, Enagás, Iberdrola, Air Liquide, Microsoft, Bayer, Capital One ...	02-20
Cinco valores que se deben tener muy en cuenta por técnico este martes	02-20
Almirall : le titre bondit après un accord avec Novo Nordisk	02-19
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	02-19
Les prix américains plombent un peu l'ambiance	02-19
En Direct des Marchés : Alstom, Forvia, Veolia, Casino, Apple, Nintendo, Super Micro Computer...	02-19
EN DIRECTO DESDE LOS MERCADOS: Almirall, Santander, CaixaBank, Iberdrola, Apple, Repsol, Nintendo, Super Micro Computer...	02-19
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	02-19
Almirall, S.A. Provides Earnings Guidance for the Year 2024	02-19
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-18
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	12-21
Almirall S A : inicia el primer estudio clínico en fase I de ALM223, una IL-2muFc para enfermedades autoinmunes	12-21
Almirall S A : participará en la 42ª edición anual de la J.P. Morgan Healthcare Conference	12-19
Almirall : alliance avec le belge etherna dans l'ARN messager	12-12
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies	12-12
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology	12-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Almirall, S.A.

Equities

ALM

ES0157097017

Other languages

Filters